It is interesting to see the document specifically allows the commencement of the CLEVER trial with Yervoy(BMS). I hope that Viralytics really does carry on with 'business as usual' because we have many months before resolution of this offer. They actually need to double down on the gathering data and increase the perceived value of CAVATAK. If the trails go well, Merck will need to pay more.
